TB31F

BIOLOGICAL2 trials

Sponsors

Radboud University Medical Center

Conditions

Malaria,Falciparum

Phase 1

Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F

CompletedNCT04238689

Radboud University Medical CenterMalaria,Falciparum

Start: 2020-02-14End: 2021-03-04Updated: 2023-03-27

Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali

CompletedNCT06413108

Radboud University Medical CenterMalaria,Falciparum

Start: 2024-07-12End: 2026-01-16Updated: 2026-01-22

Related Papers

Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.

2022-08-1032 citations